FDA NEWS RELEASE For Immediate Release: March 29, 2013Media Inquiries: Morgan Liscinsky, 301-796-0397; morgan.liscinsky@fda.hhs.gov Consumer Inquiries: 888-INFO-FDA FDA approves Invokana to treat type 2 diabetesFirst in a new class of diabetes drugs The U.S. Food and Drug Administration today approved Invokana (canagliflozin) tablets, used with diet and exercise, to improve glycemic control in adults with…
The goal of this clinical research study is to learn if treating stem cell donors with filgrastim (G-CSF) and plerixafor (Mozobil®) can cause them to produce a higher number of blood stem cells than filgrastim by itself. Researchers also want to learn if giving both of these drugs helps donors produce enough stem cells so…
The main objective of the study is to monitor health outcomes associated with antiretroviral drugs in a population of HIV-infected patients. Article source: http://clinicaltrials.gov/ct2/show/NCT01078233?term=hiv&lup_s=02%2F23%2F2013&lup_d=30
Whether or not to allot antidepressants to kids is a difficult issue. Medical professionals need to have adequate training to know a impact antidepressants have on their patients. Frisco, TX (PRWEB) Mar 23, 2013 Suicide attorney Skip Simpson of a Law Offices of Skip Simpson pronounced currently psychiatrists who allot antidepressants should be wakeful of…
As a measure of secondary prophylaxis, and with the final objective of avoiding the infection, it has been suggested to use antiretroviral therapy. This is known as post-exposure prophylaxis (PEP). Although there are different recommendations, almost every guideline recommend using 3 drugs as PEP both in USA and Europe. Toxicity is one of the main…
weight detriment solutions Eat Drink Shrink Plan is a useful beam that provides users with weight detriment solutions that assistance them remove weight quickly. Is it safe? Seattle, Wa Mar 23, 2013 Eat Drink Shrink Plan is a latest module grown by Danette May, who claims to give people weight detriment solutions that assistance them…
Chronic hepatitis C virus (HCV) is a major cause of morbidity and mortality worldwide with an estimated number of 180 million infected patients. Until 2012 the current standard of care (SOC) treatment of patients with chronic hepatitis C was a 24 to 72 weeks therapy with pegylated interferon- and ribavirin (PR). In 2012, the protease-inhibitors…
